Exhibit
|
|
Description
|
99.1
|
|
|
99.2
|
|
|
99.3
|
|
|
99.4
|
|
|
|
|
|
|
|
|
AETERNA ZENTARIS INC.
|
||
|
|
|
|
|
Date: May 7, 2019
|
|
By:
|
|
/s/ Michael V. Ward
|
|
|
|
|
Michael V. Ward
|
|
|
|
|
Chief Executive Officer
|
Aeterna Zentaris Inc.
|
||
Condensed Interim Consolidated Financial Statements
|
||
(Unaudited)
|
||
As at March 31, 2019 and for the three-month periods ended March 31, 2019 and 2018
|
Aeterna Zentaris Inc.
|
||
Condensed Interim Consolidated Statements of Financial Position
|
||
(in thousands of US dollars)
|
(Unaudited)
|
|
March 31, 2019
|
|
December 31, 2018
|
||
|
|
$
|
|
$
|
||
ASSETS
|
|
|
|
|
||
Current assets
|
|
|
|
|
||
Cash and cash equivalents
|
|
11,357
|
|
|
14,512
|
|
Trade and other receivables (note 6)
|
|
612
|
|
|
294
|
|
Inventory
|
|
540
|
|
|
240
|
|
Prepaid expenses and other current assets
|
|
894
|
|
|
1,210
|
|
Total current assets
|
|
13,403
|
|
|
16,256
|
|
Restricted cash equivalents
|
|
363
|
|
|
418
|
|
Right of use assets (note 4)
|
|
451
|
|
|
—
|
|
Property, plant and equipment
|
|
59
|
|
|
65
|
|
Identifiable intangible assets
|
|
55
|
|
|
62
|
|
Goodwill
|
|
8,053
|
|
|
8,210
|
|
Total assets
|
|
22,384
|
|
|
25,011
|
|
LIABILITIES
|
|
|
|
|
||
Current liabilities
|
|
|
|
|
||
Payables and accrued liabilities (note 7)
|
|
2,668
|
|
|
2,966
|
|
Provision for restructuring and other costs (note 8)
|
|
200
|
|
|
887
|
|
Income taxes payable
|
|
1,637
|
|
|
1,669
|
|
Current portion of deferred revenues
|
|
74
|
|
|
74
|
|
Current portion of lease liabilities (note 4)
|
|
624
|
|
|
—
|
|
Current portion of warrant liability (note 9)
|
|
420
|
|
|
—
|
|
Total current liabilities
|
|
5,623
|
|
|
5,596
|
|
Deferred revenues
|
|
240
|
|
|
258
|
|
Lease liabilities (note 4)
|
|
718
|
|
|
—
|
|
Warrant liability (note 9)
|
|
5,275
|
|
|
3,634
|
|
Employee future benefits (note 10)
|
|
13,647
|
|
|
13,205
|
|
Non-current portion of provision for restructuring and other costs (note 8)
|
|
441
|
|
|
411
|
|
Total liabilities
|
|
25,944
|
|
|
23,104
|
|
SHAREHOLDERS' (DEFICIENCY) EQUITY
|
|
|
|
|
||
Share capital
|
|
222,335
|
|
|
222,335
|
|
Other capital
|
|
89,437
|
|
|
89,342
|
|
Deficit
|
|
(315,427
|
)
|
|
(309,781
|
)
|
Accumulated other comprehensive income
|
|
95
|
|
|
11
|
|
Total shareholders' (deficiency) equity
|
|
(3,560
|
)
|
|
1,907
|
|
Total liabilities and shareholders' (deficiency) equity
|
|
22,384
|
|
|
25,011
|
|
/s/ Carolyn Egbert
|
|
/s/ Gérard Limoges
|
Carolyn Egbert
Chair of the Board
|
|
Gérard Limoges
Director
|
Aeterna Zentaris Inc.
|
||
Condensed Interim Consolidated Statements of Changes in Shareholders' (Deficiency) Equity
|
||
For the three months ended March 31, 2019 and 2018
|
||
(in thousands of US dollars, except share data)
|
(Unaudited)
|
Common shares (number of)
1
|
|
Share capital
|
|
Other capital
|
|
Deficit
|
|
Accumulated other comprehensive income (loss)
|
|
Total
|
||||||
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
||||||
Balance - January 1, 2019
|
16,440,760
|
|
|
222,335
|
|
|
89,342
|
|
|
(309,781
|
)
|
|
11
|
|
|
1,907
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,911
|
)
|
|
—
|
|
|
(4,911
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign currency translation adjustments
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
84
|
|
|
84
|
|
Actuarial loss on defined benefit plan (note 10)
|
—
|
|
|
—
|
|
|
—
|
|
|
(735
|
)
|
|
—
|
|
|
(735
|
)
|
Comprehensive income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,646
|
)
|
|
84
|
|
|
(5,562
|
)
|
Share-based compensation costs
|
—
|
|
|
—
|
|
|
95
|
|
|
—
|
|
|
—
|
|
|
95
|
|
Balance - March 31, 2019
|
16,440,760
|
|
|
222,335
|
|
|
89,437
|
|
|
(315,427
|
)
|
|
95
|
|
|
(3,560
|
)
|
(Unaudited)
|
|
Common shares (number of)
1
|
|
Share capital
|
|
Other capital
|
|
Deficit
|
|
Accumulated other comprehensive income (loss)
|
|
Total
|
||||||
|
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
||||||
Balance - January 1, 2018
|
|
16,440,760
|
|
|
222,335
|
|
|
88,772
|
|
|
(314,161
|
)
|
|
271
|
|
|
(2,783
|
)
|
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
14,424
|
|
|
—
|
|
|
14,424
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign currency translation adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(222
|
)
|
|
(222
|
)
|
Comprehensive loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
14,424
|
|
|
(222
|
)
|
|
14,202
|
|
Share-based compensation costs
|
|
—
|
|
|
—
|
|
|
123
|
|
|
—
|
|
|
—
|
|
|
123
|
|
Balance - March 31, 2018
|
|
16,440,760
|
|
|
222,335
|
|
|
88,895
|
|
|
(299,737
|
)
|
|
49
|
|
|
11,542
|
|
1
|
Issued and paid in full.
|
Aeterna Zentaris Inc.
|
||
Condensed Interim Consolidated Statements of Comprehensive (Loss) Income
|
||
For the three months ended March 31, 2019 and 2018
|
||
(in thousands of US dollars, except share and per share data)
|
|
|
Three months ended March 31,
|
||||
(Unaudited)
|
|
2019
|
|
2018
|
||
|
|
$
|
|
$
|
||
Revenues
|
|
|
|
|
||
Royalty income (note 5)
|
|
13
|
|
|
—
|
|
Licensing revenue (note 5)
|
|
18
|
|
|
24,568
|
|
Sales commission and other
|
|
6
|
|
|
90
|
|
Total revenues
|
|
37
|
|
|
24,658
|
|
|
|
|
|
|
||
Operating expenses
|
|
|
|
|
||
Research and development costs
|
|
528
|
|
|
833
|
|
General and administrative expenses
|
|
1,637
|
|
|
2,786
|
|
Selling expenses
|
|
304
|
|
|
1,641
|
|
Impairment of right of use asset (note 4)
|
|
337
|
|
|
—
|
|
Write-off of other current assets
|
|
169
|
|
|
—
|
|
Total operating expenses
|
|
2,975
|
|
|
5,260
|
|
(Loss) income from operations
|
|
(2,938
|
)
|
|
19,398
|
|
|
|
|
|
|
||
Gain due to changes in foreign currency exchange rates
|
|
64
|
|
|
48
|
|
Fair value (loss) gain on warrant liability (note 9)
|
|
(2,061
|
)
|
|
1,828
|
|
Other finance income
|
|
24
|
|
|
18
|
|
Net finance (loss) income
|
|
(1,973
|
)
|
|
1,894
|
|
(Loss) income before income taxes
|
|
(4,911
|
)
|
|
21,292
|
|
Income tax expense
|
|
—
|
|
|
(6,868
|
)
|
Net (loss) income
|
|
(4,911
|
)
|
|
14,424
|
|
Other comprehensive (loss) income:
|
|
|
|
|
||
Items that may be reclassified subsequently to profit or loss:
|
|
|
|
|
||
Foreign currency translation adjustments
|
|
84
|
|
|
(222
|
)
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
||
Actuarial loss on defined benefit plans
|
|
(735
|
)
|
|
—
|
|
Comprehensive (loss) income
|
|
(5,562
|
)
|
|
14,202
|
|
Net (loss) income per share [basic]
|
|
(0.30
|
)
|
|
0.88
|
|
Net (loss) income per share [diluted]
|
|
(0.30
|
)
|
|
0.87
|
|
Weighted average number of shares outstanding (note 17):
|
|
|
|
|
||
Basic
|
|
16,440,760
|
|
|
16,440,760
|
|
Diluted
|
|
16,440,760
|
|
|
16,493,363
|
|
Aeterna Zentaris Inc.
|
||
Condensed Interim Consolidated Statements of Cash Flows
|
||
For the three months ended March 31, 2019 and 2018
|
||
(in thousands of US dollars)
|
|
|
Three months ended March 31,
|
||||
(Unaudited)
|
|
2019
|
|
2018
|
||
|
|
$
|
|
$
|
||
Cash flows from operating activities
|
|
|
|
|
||
Net (loss) income for the period
|
|
(4,911
|
)
|
|
14,424
|
|
Items not affecting cash and cash equivalents:
|
|
|
|
|
||
Change in fair value of warrant liability (note 9)
|
|
2,061
|
|
|
(1,828
|
)
|
Provision for restructuring costs (note 8)
|
|
(17
|
)
|
|
(219
|
)
|
Depreciation and amortization
|
|
66
|
|
|
14
|
|
Impairment of right of use asset (note 4)
|
|
337
|
|
|
—
|
|
Write-off of other current assets
|
|
169
|
|
|
—
|
|
Deferred income taxes
|
|
—
|
|
|
3,479
|
|
Share-based compensation costs
|
|
95
|
|
|
123
|
|
Employee future benefits (note 10)
|
|
134
|
|
|
78
|
|
Amortization of deferred revenues
|
|
(18
|
)
|
|
(541
|
)
|
Foreign exchange loss (gain) on items denominated in foreign currencies
|
|
(45
|
)
|
|
(100
|
)
|
(Gain) loss on disposal of property, plant and equipment
|
|
(3
|
)
|
|
9
|
|
Other non-cash items
|
|
—
|
|
|
16
|
|
Changes in operating assets and liabilities (note 13)
|
|
(874
|
)
|
|
1,262
|
|
Net cash (used in) provided by operating activities
|
|
(3,006
|
)
|
|
16,717
|
|
Cash flows from financing activities
|
|
|
|
|
||
Payments on lease liabilities
|
|
(151
|
)
|
|
—
|
|
Net cash provided by financing activities
|
|
(151
|
)
|
|
—
|
|
Cash flows from investing activities
|
|
|
|
|
||
Proceeds from disposal of property, plant and equipment
|
|
—
|
|
|
11
|
|
Change in restricted cash equivalents
|
|
50
|
|
|
—
|
|
Net cash provided by investing activities
|
|
50
|
|
|
11
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
(48
|
)
|
|
40
|
|
Net change in cash and cash equivalents
|
|
(3,155
|
)
|
|
16,768
|
|
Cash and cash equivalents – Beginning of period
|
|
14,512
|
|
|
7,780
|
|
Cash and cash equivalents – End of period
|
|
11,357
|
|
|
24,548
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
2019
|
|
|
|
|
|
Operating lease commitments disclosed as at December 31, 2018
|
|
1,620
|
|
|
|
|
|
Discounted using the lessee’s incremental borrowing rate of at the date of initial application:
|
|
|
|
|
|
|
|
Lease liability recognized as at January 1, 2019
|
|
1,522
|
|
Current lease liabilities
|
|
629
|
|
Non-current lease liabilities
|
|
893
|
|
|
|
|
|
During the three-month period ended March 31, 2019
|
|
|
|
Cash lease payments made
|
|
171
|
|
Interest paid as charged to comprehensive income (loss) as other finance income
|
|
20
|
|
Payments against lease liabilites
|
|
151
|
|
|
|
|
|
Lease liability recognized as at March 31, 2019
|
|
1,342
|
|
Current lease liabilities
|
|
624
|
|
Non-current lease liabilities
|
|
718
|
|
|
|
|
$
|
|
Less than 1 year
|
|
|
624
|
|
1 - 3 years
|
|
|
704
|
|
4 - 5 years
|
|
|
14
|
|
More than 5 years
|
|
|
—
|
|
Total
|
|
|
1,342
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
March 31,
|
|
January 1,
|
|
|
2019
|
|
2019
|
Gross right of use assets
|
|
|
|
|
Building
|
|
383
|
|
735
|
Cars and equipment
|
|
122
|
|
124
|
Total
|
|
505
|
|
859
|
|
|
|
|
|
Accumulated amortization
|
|
|
|
|
Building
|
|
(41)
|
|
—
|
Cars and equipment
|
|
(13)
|
|
—
|
Total
|
|
(54)
|
|
—
|
|
|
|
|
|
Net right of use assets
|
|
|
|
|
Building
|
|
342
|
|
735
|
Cars and equipment
|
|
109
|
|
124
|
Total
|
|
451
|
|
859
|
|
|
|
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
March 31,
|
|
December 31,
|
||
|
2019
|
|
2018
|
||
|
$
|
|
$
|
||
Trade accounts receivable (net of allowance for doubtful accounts of $55 (December 31, 2018 - $55)
|
313
|
|
|
142
|
|
Value added tax
|
284
|
|
|
49
|
|
Other
|
15
|
|
|
103
|
|
|
612
|
|
|
294
|
|
|
|
March 31,
|
|
December 31,
|
||
|
|
2019
|
|
2018
|
||
|
|
$
|
|
$
|
||
Trade accounts payable
|
|
964
|
|
|
1,282
|
|
Accrued research and development costs
|
|
—
|
|
|
26
|
|
Salaries, employment taxes and benefits
|
|
232
|
|
|
183
|
|
Financing of insurance premiums (a)
|
|
416
|
|
|
738
|
|
Other accrued liabilities
|
|
1,056
|
|
|
737
|
|
|
|
2,668
|
|
|
2,966
|
|
(a)
|
Represents financing of the Company's 2019 insurance premiums, carrying interest at 6.5% and repayable in eight equal monthly installments commencing January 31, 2019.
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Cetrotide
(R)
onerous contracts
|
|
2017 German Restructuring: onerous lease
|
|
2017 German Restructuring: severance
|
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Balance – January 1, 2019
|
|
547
|
|
|
663
|
|
|
88
|
|
|
1,298
|
|
|
|
|
|
|
|
|
|
—
|
|
|||
Adoption of IFRS 16 (note 4)
|
|
—
|
|
|
(663
|
)
|
|
—
|
|
|
(663
|
)
|
Utilization of provision
|
|
(52
|
)
|
|
—
|
|
|
—
|
|
|
(52
|
)
|
Change in provision
|
|
60
|
|
|
—
|
|
|
9
|
|
|
69
|
|
Impact of foreign exchange rate changes
|
|
(11
|
)
|
|
—
|
|
|
—
|
|
|
(11
|
)
|
Balance – March 31, 2019
|
|
544
|
|
|
—
|
|
|
97
|
|
|
641
|
|
Less current portion
|
|
(103
|
)
|
|
—
|
|
|
(97
|
)
|
|
(200
|
)
|
Non-current portion
|
|
441
|
|
|
—
|
|
|
—
|
|
|
441
|
|
|
Three months ended March 31, 2019
|
|
|
$
|
|
Balance – January 1, 2019
|
3,634
|
|
Change in fair value of warrant liability
|
2,061
|
|
Balance – March 31, 2019
|
5,695
|
|
Current portion of warrant liability
|
420
|
|
Long-term portion of warrant liability
|
5,275
|
|
|
|
Three months ended March 31, 2019
|
|
Year ended December 31, 2018
|
|
||||||||
|
|
Number
|
|
Weighted average exercise price
|
|
Number
|
|
Weighted average exercise price
|
|
||||
|
|
|
|
$
|
|
|
|
$
|
|
||||
Balance – Beginning of period
|
|
3,391,844
|
|
|
6.23
|
|
|
3,417,840
|
|
|
7.59
|
|
|
Expired
|
|
—
|
|
|
—
|
|
|
(25,996
|
)
|
|
185.00
|
|
|
Balance – End of period
|
|
3,391,844
|
|
|
6.23
|
|
|
3,391,844
|
|
|
6.23
|
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Number of equivalent shares
|
|
Market value per share price
|
|
Weighted average exercise price
|
|
Risk-free annual interest rate
|
|
Expected volatility
|
|
Expected life (years)
|
|
Expected dividend yield
|
||||||
|
|
|
|
($)
|
|
($)
|
|
(a)
|
|
(b)
|
|
(c)
|
|
(d)
|
||||||
March 2015 Series A Warrants (e)
|
|
115,844
|
|
|
4.65
|
|
|
1.07
|
|
|
2.39
|
%
|
|
82.13
|
%
|
|
0.94
|
|
0.00
|
%
|
December 2015 Warrants
|
|
2,331,000
|
|
|
4.65
|
|
|
7.10
|
|
|
2.29
|
%
|
|
102.66
|
%
|
|
1.71
|
|
0.00
|
%
|
November 2016 Warrants (f)
|
|
945,000
|
|
|
4.65
|
|
|
4.70
|
|
|
2.37
|
%
|
|
80.38
|
%
|
|
1.09
|
|
0.00
|
%
|
(a)
|
Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
|
(b)
|
Based on the historical volatility of the Company's stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations.
|
(c)
|
Based upon time to expiry from the reporting period date.
|
(d)
|
The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
|
(e)
|
For the March 2015 Series A Warrants, the inputs and assumptions applied to the Black-Scholes option pricing model have been further adjusted to take into consideration the value attributed to certain anti-dilution provisions. Specifically, the weighted average exercise price is subject to adjustment (see
note 11 - Share and other capital
).
|
(f)
|
For the November 2016 Warrants, the Company reduced the fair value of these warrants to take into consideration the fair value of the
$10.00
call option, which was also calculated using the Black-Scholes pricing model.
|
|
|
Three months ended March 31, 2019
|
Year ended December 31, 2018
|
||||||||
|
|
Pension benefit plans
|
|
Other benefit plans
|
|
Total
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
$
|
||||
Balances – Beginning of the period
|
|
13,100
|
|
|
105
|
|
|
13,205
|
|
14,229
|
|
Current service cost
|
|
13
|
|
|
2
|
|
|
15
|
|
72
|
|
Interest cost
|
|
55
|
|
|
—
|
|
|
55
|
|
225
|
|
Actuarial loss (gain) arising from changes in financial assumptions
|
|
735
|
|
|
—
|
|
|
735
|
|
(174
|
)
|
Benefits paid
|
|
(109
|
)
|
|
—
|
|
|
(109
|
)
|
(494
|
)
|
Impact of foreign exchange rate changes
|
|
(252
|
)
|
|
(2
|
)
|
|
(254
|
)
|
(653
|
)
|
Balances – End of the period
|
|
13,542
|
|
|
105
|
|
|
13,647
|
|
13,205
|
|
Amounts recognized:
|
|
|
|
|
|
|
|
||||
In net loss
|
|
(68
|
)
|
|
(2
|
)
|
|
(70
|
)
|
(316
|
)
|
In other comprehensive loss
|
|
(483
|
)
|
|
2
|
|
|
(481
|
)
|
846
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Three months ended March 31,
|
|
Year ended December 31,
|
||||||||
|
|
2019
|
|
2018
|
||||||||
US dollar-denominated stock options and DSU
|
|
Number
|
|
Weighted average exercise price
(US$) |
|
Number
|
|
Weighted average exercise price
(US$) |
||||
Balance – Beginning of the period
|
|
888,816
|
|
|
3.66
|
|
|
712,415
|
|
|
4.66
|
|
Granted
|
|
—
|
|
|
—
|
|
|
426,000
|
|
|
1.74
|
|
Forfeited
|
|
—
|
|
|
—
|
|
|
(249,599
|
)
|
|
3.23
|
|
Balance – End of period
|
|
888,816
|
|
|
3.66
|
|
|
888,816
|
|
|
3.66
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Three months ended March 31,
|
|
Year ended December 31,
|
||||||||
|
|
2019
|
|
2018
|
||||||||
Canadian dollar-denominated options
|
|
Number
|
|
Weighted average exercise price
(CAN$) |
|
Number
|
|
Weighted average exercise price
(CAN$) |
||||
Balance – Beginning of the period
|
|
869
|
|
|
743.56
|
|
|
1,503
|
|
|
605.84
|
|
Forfeited
|
|
—
|
|
|
—
|
|
|
(104
|
)
|
|
668.65
|
|
Expired
|
|
—
|
|
|
—
|
|
|
(530
|
)
|
|
367.70
|
|
Balance – End of the period
|
|
869
|
|
|
743.56
|
|
|
869
|
|
|
743.56
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Three months ended March 31,
|
|
||||
|
|
2019
|
|
2018
|
|
||
|
|
$
|
|
$
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Trade and other receivables
|
|
(329
|
)
|
|
(80
|
)
|
|
Inventory
|
|
(305
|
)
|
|
(437
|
)
|
|
Prepaid expenses and other current assets
|
|
144
|
|
|
(171
|
)
|
|
Payables and accrued liabilities
|
|
(255
|
)
|
|
135
|
|
|
Provision for restructuring costs
|
|
—
|
|
|
(1,352
|
)
|
|
Income taxes payable
|
|
—
|
|
|
3,300
|
|
|
Employee future benefits
|
|
(109
|
)
|
|
(117
|
)
|
|
Lease liabilities
|
|
(20
|
)
|
|
—
|
|
|
Provisions and other non-current liabilities
|
|
—
|
|
|
(16
|
)
|
|
|
|
(874
|
)
|
|
1,262
|
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
March 31, 2019
|
|
Financial assets at amortized cost
|
|
Financial
liabilities at FVTPL |
|
Financial
liabilities at amortized cost |
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Cash and cash equivalents
*
|
|
11,357
|
|
|
—
|
|
|
—
|
|
|
11,357
|
|
Trade and other receivables
|
|
328
|
|
|
—
|
|
|
—
|
|
|
328
|
|
Restricted cash equivalents
|
|
363
|
|
|
—
|
|
|
—
|
|
|
363
|
|
Payables and accrued liabilities
|
|
—
|
|
|
—
|
|
|
(2,668
|
)
|
|
(2,668
|
)
|
Restructuring and other costs
|
|
—
|
|
|
—
|
|
|
(641
|
)
|
|
(641
|
)
|
Warrant liability
|
|
—
|
|
|
(5,695
|
)
|
|
—
|
|
|
(5,695
|
)
|
|
|
12,048
|
|
|
(5,695
|
)
|
|
(3,309
|
)
|
|
3,044
|
|
December 31, 2018
|
|
Financial assets at amortized cost
|
|
Financial
liabilities at FVTPL |
|
Financial
liabilities at amortized cost |
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Cash and cash equivalents
*
|
|
14,512
|
|
|
—
|
|
|
—
|
|
|
14,512
|
|
Trade and other receivables
|
|
245
|
|
|
—
|
|
|
—
|
|
|
245
|
|
Restricted cash equivalents
|
|
418
|
|
|
—
|
|
|
—
|
|
|
418
|
|
Payables and accrued liabilities
|
|
—
|
|
|
—
|
|
|
(2,940
|
)
|
|
(2,940
|
)
|
Restructuring and other costs
|
|
—
|
|
|
—
|
|
|
(1,298
|
)
|
|
(1,298
|
)
|
Warrant liability
|
|
—
|
|
|
(3,634
|
)
|
|
—
|
|
|
(3,634
|
)
|
|
|
15,175
|
|
|
(3,634
|
)
|
|
(4,238
|
)
|
|
7,303
|
|
Level 1 –
|
Unadjusted quoted prices in active markets for identical assets or liabilities.
|
Level 2 –
|
Inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e. prices) or indirectly (i.e. derived from prices).
|
Level 3 –
|
Inputs for an asset or liability that are not based on observable market data (unobservable inputs).
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
(a)
|
Credit risk
|
(b)
|
Liquidity risk
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Carrying
amount |
|
-30%
|
|
+30%
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Warrant liability
|
|
5,695
|
|
|
2,463
|
|
|
(2,944
|
)
|
Total impact on net loss – decrease / (increase)
|
|
|
|
2,463
|
|
|
(2,944
|
)
|
|
|
Three months ended March 31,
|
|
||||
|
|
2019
|
|
2018
|
|
||
|
|
$
|
|
$
|
|
||
Net (loss) income
|
|
(4,911
|
)
|
|
14,424
|
|
|
Basic weighted average number of shares outstanding
|
|
16,440,760
|
|
|
16,440,760
|
|
|
Net (loss) income per share [basic]
|
|
(0.30
|
)
|
|
0.88
|
|
|
|
|
|
|
|
|
||
Dilutive effect of share purchase warrants
|
|
—
|
|
|
52,603
|
|
|
Diluted weighted average number of shares outstanding
|
|
16,440,760
|
|
|
16,493,363
|
|
|
Net (loss) income per share [diluted]
|
|
(0.30
|
)
|
|
0.87
|
|
|
|
|
|
|
|
|
||
Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect
|
|
|
|
|
|
||
Stock options
|
|
889,685
|
|
|
710,196
|
|
|
Warrants (number of equivalent shares)
|
|
3,391,844
|
|
|
3,301,996
|
|
|
Aeterna Zentaris Inc.
|
||
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
||
As at March 31, 2019 and for the three months ended March 31, 2019 and 2018
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted)
|
|
|
Three months ended March 31,
|
|
||||
(in thousands, except share and per share data)
|
|
2019
|
|
2018
|
|
||
|
|
$
|
|
$
|
|
||
Revenues
|
|
|
|
|
|
||
Royalty income
|
|
13
|
|
|
—
|
|
|
Licensing revenue
|
|
18
|
|
|
24,568
|
|
|
Sales commission and other
|
|
6
|
|
|
90
|
|
|
Total revenues
|
|
37
|
|
|
24,658
|
|
|
|
|
|
|
|
|
||
Research and development costs
|
|
528
|
|
|
833
|
|
|
General and administrative expenses
|
|
1,637
|
|
|
2,786
|
|
|
Selling expenses
|
|
304
|
|
|
1,641
|
|
|
Impairment of right of use asset
|
|
337
|
|
|
—
|
|
|
Write-off of other current assets
|
|
169
|
|
|
—
|
|
|
Total operating expenses
|
|
2,975
|
|
|
5,260
|
|
|
|
|
|
|
|
|
||
(Loss) income from operations
|
|
(2,938
|
)
|
|
19,398
|
|
|
Net finance (loss) income
|
|
(1,973
|
)
|
|
1,894
|
|
|
(Loss) income before income taxes
|
|
(4,911
|
)
|
|
21,292
|
|
|
Income tax expense
|
|
—
|
|
|
(6,868
|
)
|
|
Net (loss) income
|
|
(4,911
|
)
|
|
14,424
|
|
|
Total other comprehensive income (loss) adjustments
|
|
(651
|
)
|
|
(222
|
)
|
|
Comprehensive (loss) income
|
|
(5,562
|
)
|
|
14,202
|
|
|
|
|
|
|
|
|
||
Net (loss) income per share [basic]
|
|
(0.30
|
)
|
|
0.88
|
|
|
Net (loss) income per share [diluted]
|
|
(0.30
|
)
|
|
0.87
|
|
|
Weighted average number of shares outstanding:
|
|
|
|
|
|
||
Basic
|
|
16,440,760
|
|
|
16,440,760
|
|
|
Diluted
|
|
16,440,760
|
|
|
16,493,363
|
|
|
(in thousands, except share and per share data)
|
|
As at March 31,
|
|
As at December 31,
|
||
|
|
2019
|
|
2018
|
||
|
|
$
|
|
$
|
||
Cash and cash equivalents
|
|
11,357
|
|
|
14,512
|
|
Trade and other receivables and other current assets
|
|
1,506
|
|
|
1,504
|
|
Inventory
|
|
540
|
|
|
240
|
|
Restricted cash equivalents
|
|
363
|
|
|
418
|
|
Property, plant and equipment
|
|
59
|
|
|
65
|
|
Right of use asset
|
|
451
|
|
|
—
|
|
Other non-current assets
|
|
8,108
|
|
|
8,272
|
|
Total assets
|
|
22,384
|
|
|
25,011
|
|
Payables and other current liabilities
|
|
2,668
|
|
|
2,966
|
|
Current portion of deferred revenues
|
|
74
|
|
|
74
|
|
Warrant liability
|
|
5,695
|
|
|
3,634
|
|
Current provision for restructuring costs and other costs
|
|
200
|
|
|
887
|
|
Taxes payable
|
|
1,637
|
|
|
1,669
|
|
Employee future benefits
|
|
13,647
|
|
|
13,205
|
|
Lease liabilities
|
|
1,342
|
|
|
—
|
|
Long-term portion of restructuring and other costs and deferred revenues
|
|
681
|
|
|
669
|
|
Total liabilities
|
|
25,944
|
|
|
23,104
|
|
Shareholders' (deficiency) equity
|
|
(3,560
|
)
|
|
1,907
|
|
Total liabilities and shareholders' equity (deficiency)
|
|
22,384
|
|
|
25,011
|
|
(in thousands, except for per share data)
|
|
Three months ended
|
||||||||||
|
|
March 31, 2019
|
|
December 31, 2018
|
|
September 30, 2018
|
|
June 30, 2018
|
||||
|
|
$
|
|
|
|
|
|
$
|
||||
Revenues
|
|
37
|
|
|
1,392
|
|
|
663
|
|
|
168
|
|
Net (loss) income
|
|
(4,911
|
)
|
|
(5,126
|
)
|
|
(2,509
|
)
|
|
(2,602
|
)
|
Net (loss) income per share [basic]*
|
|
(0.30
|
)
|
|
(0.31
|
)
|
|
(0.15
|
)
|
|
(0.16
|
)
|
Net (loss) income per share [diluted]*
|
|
(0.30
|
)
|
|
(0.31
|
)
|
|
(0.15
|
)
|
|
(0.16
|
)
|
(in thousands, except for per share data)
|
|
Three months ended
|
||||||||||
|
|
March 31, 2018
|
|
December 31, 2017
|
|
September 30, 2017
|
|
June 30, 2017
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Revenues
|
|
24,658
|
|
|
178
|
|
|
241
|
|
|
243
|
|
Net loss
|
|
14,424
|
|
|
(484
|
)
|
|
(9,631
|
)
|
|
(2,550
|
)
|
Net (loss) per share [basic]*
|
|
0.88
|
|
|
(0.03
|
)
|
|
(0.61
|
)
|
|
(0.18
|
)
|
Net (loss) income per share [diluted]*
|
|
0.87
|
|
|
(0.03
|
)
|
|
(0.61
|
)
|
|
(0.18
|
)
|
*
|
Net income (loss) per share is based on the weighted average number of shares outstanding during each reporting period, which may differ on a quarter-to-quarter basis. As such, the sum of the quarterly net loss per share amounts may not equal full-year net loss per share.
|
(in thousands)
|
Three months ended March 31,
|
||||
|
2019
|
|
2018
|
||
|
|
|
|
||
Cash and cash equivalents - Beginning of period
|
14,512
|
|
|
7,780
|
|
Cash flows from operating activities:
|
|
|
|
||
Net cash (used in) provided by operating activities
|
(3,006
|
)
|
|
16,717
|
|
Cash flows from financing activities:
|
|
|
|
||
Net cash used in financing activities
|
(151
|
)
|
|
—
|
|
Cash flows from investing activities:
|
|
|
|
||
Net cash provided by investing activities
|
50
|
|
|
11
|
|
Effect of exchange rate changes on cash and cash equivalents
|
(48
|
)
|
|
40
|
|
Cash and cash equivalents - End of period
|
11,357
|
|
|
24,548
|
|
|
Warrants
|
Exercise Price
|
Expiry date
|
|
|
#
|
$
|
|
|
March 2015 registered direct offering - Series A
|
115,844
|
|
1.07
|
March 10, 2020
|
December 2015 registered direct offering
|
2,331,000
|
|
7.10
|
December 13, 2020
|
November 2016 registered direct offering
|
945,000
|
|
4.70
|
May 1, 2020
|
|
3,391,844
|
|
|
|
(in thousands)
|
|
Service and manufacturing
|
|
|
|
$
|
|
Less than 1 year
|
|
2,049
|
|
1 - 3 years
|
|
25
|
|
4 - 5 years
|
|
21
|
|
More than 5 years
|
|
33
|
|
Total
|
|
2,128
|
|
A.
|
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
I.
|
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
II.
|
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
B.
|
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
|
/s/ Michael V. Ward
|
Michael V. Ward
|
President and Chief Executive Officer
|
A.
|
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
I.
|
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
II.
|
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
B.
|
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
|
/s/ Leslie Auld
|
Leslie Auld
|
Chief Financial Officer
|